Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...

Patients with type 2 diabetes who had initiated GLP-1 RAs were identified and compared with those initiating dipeptidyl ...

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that ...

Weight loss jabs such as Wegovy are “lifelong treatments” and most people who stop taking them will lose the effects, a ...

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.